All News - Eli Lilly and Company
WEBSeptember 13, 2024. Lilly expands manufacturing footprint in Ireland with $1.8 billion investment. September 12, 2024. With once-a-week dosing, insulin efsitora alfa delivers similar A1C reduction compared to daily insulin in …
Lilly.com | Eli Lilly and Company
WEBSep 13, 2024 · Press Releases. ALL CORPORATE FINANCIAL PRODUCT IMPACT ARCHIVE. New data show Lilly's EBGLYSS™ (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis. September 25, 2024. Tags | Product.
News Release - Eli Lilly and Company
WEBINDIANAPOLIS, May 13, 2022 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved Mounjaro™ (tirzepatide) injection, Eli Lilly and Company's (NYSE: LLY) new once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist indicated as an adjunct to diet and exercise to improve ...
News Release - Eli Lilly and Company
WEBINDIANAPOLIS, May 24, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it has more than doubled its investment in its Lebanon, Indiana, manufacturing site with a new $5.3 billion commitment, increasing the company's total investment in this site from $3.7 billion to $9 billion.
News Release - Eli Lilly and Company
WEBJul 8, 2024 · INDIANAPOLIS and WALTHAM, Mass., July 8, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Morphic Holding, Inc. (NASDAQ: MORF) today announced a definitive agreement for Lilly to acquire Morphic, a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases.
Lilly.com | Eli Lilly and Company
WEBSep 4, 2024 · INDIANAPOLIS , June 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced a collaboration with OpenAI that will allow Lilly to leverage OpenAI 's generative AI to invent novel antimicrobials to treat drug-resistant pathogens.
Eli Lilly (LLY) earnings Q2 2024 - CNBC
WEBAug 8, 2024 · Eli Lilly reported second-quarter earnings and revenue that blew past expectations and hiked its full-year revenue outlook by $3 billion as sales of its blockbuster diabetes drug Mounjaro and...
Lilly hits record high after Mounjaro fuels forecast raise, rival data
WEBAug 8 (Reuters) - Eli Lilly (LLY.N) on Tuesday raised its annual forecasts as demand for new diabetes drug Mounjaro surges ahead of a decision on its use as a weight-loss treatment, with shares...
Eli Lilly expects FDA decision on Alzheimer’s treatment ... - CNBC
WEBJul 17, 2023 · Eli Lilly is among the pharmaceutical companies racing to market new treatments for the disease after Eisai and Biogen’s drug Leqembi won FDA approval this month. The agency’s signoff on...
Eli Lilly & Co: Strong Buy Rating Amid Robust Product Growth and ...
WEB1 day ago · Chris Schott has given his Buy rating due to a combination of factors including the expected significant growth of Eli Lilly & Co’s (LLY) products and the company’s strong pipeline.